Hepatocellular Carcinoma — A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
Citation(s)
A Phase 1-2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered CF102 in Patients With Advanced Hepatocellular Carcinoma